SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma: combination chemotherapy with different Melphalan doses regimens. JAMA. 1969; 208: 1680-1685.
  • 2
    Kane RC, Farrel AT, Sridhara R, Pazdur R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after 1 prior therapy. Clin Cancer Res. 2006; 12: 2955-2960.
  • 3
    Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003; 9: 1136-1144.
  • 4
    Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010; 28: 2259-2266.
  • 5
    Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007; 110: 3557-3560.
  • 6
    Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007; 25: 3892-3801.
  • 7
    Janssen-Cilag International NV. Velcade (bortezomib). Summary of Product Characteristics. Beerse, Belgium: Janssen-Cilag International; 2009.
  • 8
    Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009; 144: 895-803.
  • 9
    Tariman JD, Love G, McCullagh E, Sandifer S. Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs. 2008; 12: 29-36.
  • 10
    Reeder CB, Reece DE, Kukreti V, et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood. 2010; 115: 3416-3417.
  • 11
    Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010; 116: 4745-4753.
  • 12
    Berenson JR, Yang HH, Sadler K, et al. Phase I/II trial assessing bortezomib and melphalan. J Clin Oncol. 2006; 24: 937-944.
  • 13
    Pulsoni A, Villiva N, Cavalieri E, et al. Continuous low dose of melphalan and prednisone in patients with multiple myeloma of very old age or severe associated disease. Drugs Aging. 2002; 19: 947-953.
  • 14
    Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood. 2002; 99: 3163-3168.
  • 15
    Durie BG, Harousseau JL, Miguel JS, et al. International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20: 1467-1473.
  • 16
    Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events. Version 3.0. Bethesda, MD: Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Department of Health and Human Services; 2003.
  • 17
    Bryant J, Day R. Incorporating toxicity considerations into the design of 2-stage phase II clinical trials. Biometrics. 1995; 51: 1972-1983.
  • 18
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 19
    Cox DR. Regression models and life-tables. J R Stat Soc. 1972; 34: 187-220.
  • 20
    Richardson PG, Hideshima T, Mitsiades C, Anderson KC. The emerging role of novel therapies for the treatment of relapsed myeloma. J Natl Comp Canc Netw. 2007; 5: 149-162.
  • 21
    San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359: 906-917.
  • 22
    Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010; 28: 5101-5109.
  • 23
    Mateos MV, Oriol A, Martinez-Lopez J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010; 11: 934-941.
  • 24
    Palumbo A, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood. 2007; 109: 2767-2772.
  • 25
    Berenson JR, Yang HH, Vescio RA, et al. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. Ann Hematol. 2008; 87: 623-631.
  • 26
    Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007; 357: 2123-2132.